Taselisib → canine PIK3CA (degrader engagement)

Mechanism. Taselisib (GDC-0032) is a mutant-selective PI3Kα inhibitor that selectively depletes mutant p110α via the ubiquitin-proteasome system (molecular degrader). This docking test scores POCKET ENGAGEMENT only — not degradation (which needs ternary-complex / E3 modeling) and not mutant-selectivity (the canine receptor is wild-type). A good pose is a necessary first step, not proof of a working degrader.

Survived every test the engine could run. Nothing here is proven — that's the point.

Status on the engine: evidence supported · validation-ready. Nothing here is promoted automatically — a human holds the final call.

Every idea and every result is hashed so anyone can re-derive it. Want a drug or target put to the test? Suggest one →

Have evidence, a critique, a replication, or compute to add? When contributor check-in is open you can submit a bounded packet — queued for human review, and it never changes the record on its own.

Checking whether check-in is open…